Ex-Acceleron Exec Zeldin Named Immunovant Chief Medical Officer

Four months after stepping down from Acceleron Pharma (NASDAQ: [[ticker:XLRN]]) as chief medical officer, Robert Zeldin has been appointed to the chief medical position at Immunovant. Zeldin’s experience also includes roles at Ablynx, Merck (NYSE: [[ticker:MRK]]), and Novartis (NYSE: [[ticker:NVS]]). Immunovant, which splits its operations between New York and Basel, Switzerland, is developing treatments for autoimmune diseases. The company’s lead drug candidate, IMVT-1401, is in mid-stage testing for myasthenia gravis and Graves’ ophthalmopathy.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan